Yttrium-90-Ibritumomab Tiuxetan and BuCyE High-Dose Chemotherapy Compared with BuCyE Alone As Conditioning Regimen in Patients with B-Cell Non-Hodgkin Lymphoma: IPI Matched Case Control Study At a Single Center

被引：0
|
作者：
Jo, Jae-Cheol
Yoon, Dok Hyun
Kim, Shin
Jang, Seongsoo [2 ]
Park, Chan-Jeoung [2 ]
Chi, Hyun Sook
Park, Chan-Sik [1 ]
Huh, Jooryung [1 ]
Lee, Sang-wook [3 ]
Suh, Cheolwon
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea
[2] Univ Ulsan, Asan Med Ctr, Dept Lab Med, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1581 / 1582
页数：2
相关论文
共 50 条
  • [31] Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study
    Puvvada, Soham D.
    Guillen-Rodriguez, Jose M.
    Yan, Jessica
    Inclan, Lora
    Heard, Kara
    Rivera, Xavier I.
    Anwer, Faiz
    Mahadevan, Daruka
    Schatz, Jonathan H.
    Persky, Daniel O.
    ONCOLOGY, 2018, 94 (05) : 274 - 280
  • [32] The outcome of ZBEAM, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non-Hodgkin's lymphoma (NHL).
    Krishnan, AY
    Nademanee, A
    Forman, SJ
    Fung, H
    Molina, A
    Yamauchi, D
    Spielberger, R
    Kogut, N
    Raubitschek, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 576S - 576S
  • [33] Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
    Emmanouilides, C
    Witzig, TE
    Gordon, LI
    Vo, K
    Wiseman, GA
    Flinn, IW
    Darif, M
    Schilder, RJ
    Molina, A
    LEUKEMIA & LYMPHOMA, 2006, 47 (04) : 629 - 636
  • [34] Yttrium-90 -: ibritumomab tiuxetan (Zevalin®) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S145 - S145
  • [35] The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.
    Guidetti, Anna
    Carlo-Stella, Carmelo
    Ruella, Marco
    Miceli, Rosalba
    Devizzi, Liliana
    Sia, Daniela
    Locatelli, Silvia
    Giacomini, Arianna
    Magni, Michele
    Matteucci, Paola
    Buttiglieri, Stefano
    Risso, Alessandra
    Mariani, Luigi
    Passera, Roberto
    Di Nicola, Massimo
    Tarella, Corrado
    Gianni, Alessandro M.
    BLOOD, 2010, 116 (21) : 551 - 552
  • [36] Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
    Storto, G.
    Nardelli, A.
    Pellegrino, T.
    Perna, F.
    De Falco, T.
    Erra, P.
    Ortosecco, G.
    Castaldi, E.
    Speranza, A.
    Klain, M.
    De Renzo, A.
    di Nuzzo, C.
    Pace, L.
    Rotoli, B.
    Salvatore, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S148 - S148
  • [37] Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology
    Krishnan, Amrita Y.
    Palmer, Joycelynne
    Nademanee, Auayporn R.
    Chen, Robert
    Popplewell, Leslie L.
    Tsai, Ni-Chun
    Sanchez, James F.
    Simpson, Jennifer
    Spielberger, Ricardo
    Yamauchi, Dave
    Forman, Stephen J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (06) : 922 - 929
  • [38] Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Flinn, I. W.
    Kahl, B. S.
    Frey, E. C.
    Bianco, J. A.
    Hammes, R. J.
    Webb, J.
    Swinnen, L. J.
    Sgouros, G.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 430S - 430S
  • [39] Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
    Hasenkamp, Justin
    Hess, Georg
    Hertenstein, Bernd
    Dreger, Peter
    Uharek, Lutz
    Gramatzki, Martin
    Schubert, Joerg
    Wulf, Gerald
    Truemper, Lorenz
    Schmitz, Norbert
    Glass, Bertram
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] INTERIM ANALYSIS OF POST MARKETING SURVEILLANCE OF YTTRIUM-90 IBRITUMOMAB TIUXETAN IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA
    Hatake, K.
    Kanzaki, R.
    Yabuuchi, Y.
    Kataoka, O.
    Nagai, S.
    Asaeda, Y.
    HAEMATOLOGICA, 2016, 101 : 273 - 273
12345